GRI Bio, Inc. GRI

GRI Bio presented new Phase 2a data at ERS 2026 defining GRI-0621's mechanism of action in IPF across nine mechanistic pillars. Positive Phase 2a mechanistic data on lead IPF candidate strengthens clinical validation and long-term company prospects.

GRI Bio will present late-breaking Phase 2a data on GRI-0621 at ERS 2026 showing lung function gains, anti-fibrotic biomarkers, and favorable tolerability in IPF. Positive Phase 2a IPF data presentation can drive major shifts in valuation and pipeline momentum for the company.

GRI Bio, Inc. obtained FDA Orphan Drug Designation for GRI-0621 (Tazarotene) to treat Idiopathic Pulmonary Fibrosis. Orphan Drug Designation grants GRI-0621 seven-year market exclusivity plus development incentives that strengthen regulatory and commercial positioning.

GRI Bio reported first quarter 2026 financial results, unveiled new data reinforcing GRI-0621's differentiated profile in idiopathic pulmonary fibrosis, and highlighted continued advancement of its immune-modulating pipeline. New data reinforcing GRI-0621's profile in IPF combined with pipeline progress represents significant clinical and strategic advancements likely to enhance investor sentiment and market trajectory.

Grainger H1 earnings call highlights financial results and outlook for GRI Bio, Inc. H1 earnings details can moderately shift short-term market views on GRI Bio.

GRI Bio, Inc. (GRI) received a Notice of Allowance for its UAE patent application covering novel Type 2 Diverse NKT Cell Agonists for treating inflammatory conditions. UAE patent allowance bolsters GRI's IP portfolio for innovative NKT cell agonists in inflammatory treatments, aiding competitive positioning but limited by regional scope.

GRI Bio, Inc. has reiterated its financial results for the full year 2025, highlighting improvements in its balance sheet and summarizing key recent developments. The company is focused on strengthening its financial position and advancing its strategic initiatives. The reiteration of financial results and balance sheet improvements may moderately influence investor sentiment and operational aspects.

GRI Bio, Inc. announced new Phase 2a gene expression data showing significant improvements in key drivers of fibrosis and lung repair in patients with idiopathic pulmonary fibrosis (IPF). The data highlights the potential of GRI's therapeutic approach to address critical aspects of lung disease, suggesting a positive trajectory for future clinical development and patient outcomes. The new data could significantly impact GRI's future performance and investor sentiment by demonstrating the efficacy of its treatment for a serious condition.

GRI Bio, Inc. has secured a new U.S. Composition of Matter patent that covers novel compound structures. This patent is expected to enhance the company's intellectual property portfolio and support its ongoing research and development efforts in biotechnology. The new patent could provide GRI with a competitive edge in the market by protecting its innovative compounds from potential infringement. The new patent is likely to significantly impact GRI's competitive positioning and future product development.

GRI Bio, Inc. announced a reverse stock split aimed at increasing the per-share price of its common stock. The split will be executed at a ratio of 1-for-10, meaning every ten shares will be consolidated into one share. This decision is intended to meet the minimum bid price requirement for continued listing on the Nasdaq stock exchange. The reverse split is expected to take effect on a specified date, with shareholders receiving a proportional reduction in the number of shares they hold. The reverse stock split is a strategic move to maintain Nasdaq listing requirements, which may influence market sentiment and investor confidence.

GRI Bio, Inc. announced additional positive data from its Phase 2a study of GRI-0621 in patients with idiopathic pulmonary fibrosis (IPF). The results strengthen the clinical proof-of-concept for the drug, indicating its potential effectiveness in treating this condition. The data highlights improvements in lung function and other key endpoints, supporting further development of GRI-0621 as a treatment option for IPF. Positive Phase 2a study results could significantly enhance GRI's market position and investor sentiment regarding GRI-0621.

GRI Bio, Inc. (GRI) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent developments and market performance have contributed to its visibility among investors, indicating potential shifts in market dynamics. GRI's stock movements may be influenced by broader industry trends and investor sentiment, which could impact its future trajectory. Increased trading activity suggests a moderate influence on GRI's market performance and investor sentiment.

GRI Bio, Inc. has successfully closed a public offering, raising $8.0 million. The offering consisted of 1,600,000 shares of common stock priced at $5.00 per share. The company intends to use the proceeds for general corporate purposes, including research and development and working capital. The capital raised will support research and development efforts, potentially influencing future product innovation and market positioning.

GRI Bio, Inc. has announced the pricing of a public offering amounting to $8,000,000. The offering is expected to enhance the company's financial position and support its ongoing operations and growth initiatives. The public offering is likely to provide necessary capital for operational and growth strategies, impacting financial performance moderately.

GRI Bio, Inc. announced positive topline data from its Phase 2a study in patients with Idiopathic Pulmonary Fibrosis (IPF). The study demonstrated significant improvements in key efficacy endpoints, suggesting the potential of GRI's treatment to address this serious lung disease. The company plans to advance its clinical development program based on these encouraging results. Positive Phase 2a study results could significantly enhance GRI's market position and investor sentiment.

GRI Bio, Inc. has reported interim lung function data from its ongoing Phase 2a study in patients with Idiopathic Pulmonary Fibrosis (IPF) after six weeks. The data indicates potential improvements in lung function, which may support the efficacy of GRI's treatment approach. The study aims to evaluate the safety and effectiveness of the therapy, with further results anticipated in the coming months. The interim data suggests significant potential for GRI's treatment in a critical area of unmet medical need, likely influencing investor sentiment and future market performance.

GRI Bio, Inc. (GRI) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent developments and market dynamics have contributed to its increased visibility among investors. GRI's performance is being closely monitored as it navigates through current market conditions. Increased trading activity indicates a moderately noticeable influence on GRI's market performance and investor sentiment.

GRI Bio, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference, showcasing its advancements and strategic initiatives in the biotechnology sector. The conference is a significant platform for GRI to engage with investors and highlight its growth potential and innovative projects. Participation in a prominent investment conference can enhance visibility and investor interest, potentially influencing market sentiment.

JTC Team Companies will present in the Webull Corporate Connect Webinar Series focused on Biotech and MedTech from August 19-21, 2025. GRI Bio, Inc. is among the companies participating in this event, which aims to connect investors with innovative biotech and medtech firms. Participation in the webinar may enhance visibility and investor interest, potentially influencing market sentiment and financial performance.

GRI Bio, Inc. will participate in the Webull Financial Corporate Connect Webinar Series focused on Biotech and MedTech. The event aims to provide insights into GRI's operations and future prospects within the biotech sector. Participation in the webinar may enhance investor awareness and sentiment but is not expected to significantly alter the company's trajectory.

GRI Bio, Inc. reported interim biomarker data from its ongoing Phase 2a study in patients with Idiopathic Pulmonary Fibrosis (IPF) after six weeks of treatment. The results indicate promising effects on biomarkers associated with IPF, suggesting potential therapeutic benefits. The study aims to evaluate the safety and efficacy of GRI's treatment, with further data expected in the coming months. Promising interim results in a Phase 2a study could significantly influence GRI's future performance and investor sentiment.

Marc Hertz, CEO of GRI Bio, Inc., participated in a virtual investor segment titled 'What This Means,' where he discussed the company's strategic direction and future initiatives. The segment aimed to provide insights into GRI's operations and its potential impact on the market, highlighting key developments and the company's vision moving forward. The CEO's participation in the investor segment may influence market sentiment and provide insights into the company's strategic direction.

GRI Bio, Inc. participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference, where CEO Marc Hertz discussed his commitment to the company and its innovative pipeline of Natural Killer T cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases. The on-demand video is available on virtualinvestorco.com and GRI Bio's website. GRI Bio focuses on therapies targeting NKT cells, with its lead program GRI-0621 being developed for idiopathic pulmonary fibrosis, alongside a pipeline of dNKT agonists for systemic lupus erythematosus. The participation in the conference and insights shared by the CEO may moderately influence investor sentiment and awareness of GRI Bio's innovative pipeline.

GRI Bio, Inc. has completed patient enrollment for its Phase 2a study of GRI-0621, aimed at treating Idiopathic Pulmonary Fibrosis (IPF). The study involves approximately 35 subjects and will assess the safety and tolerability of GRI-0621 compared to a placebo over 12 weeks. Interim safety results indicate that GRI-0621 is safe and well-tolerated, with no significant changes in lipid levels observed. The company expects to report interim biomarker results in July 2025 and topline data in Q3 2025, marking a significant step towards providing a new treatment option for IPF patients. Completion of enrollment and positive interim safety results indicate significant progress in developing a potentially transformative treatment for IPF.

GRI Bio, Inc. reported interim safety outcomes from a six-week trial of GRI-0621, a treatment for idiopathic pulmonary fibrosis (IPF). The results indicate that GRI-0621 was well-tolerated by participants, with no serious adverse events reported. The company aims to continue its development of GRI-0621, which could potentially address unmet needs in IPF treatment. Further data and analysis are expected as the trial progresses. The interim results suggest a positive safety profile for GRI-0621, which may influence future development and market positioning.

GRI Bio, Inc. reported positive interim safety results for GRI-0621 in a Phase 2a study for idiopathic pulmonary fibrosis (IPF). The Independent Data Monitoring Committee recommended continuing the study, noting no safety concerns in the first 24 patients evaluated. GRI-0621, a small molecule RAR-βɣ dual agonist, showed no adverse events related to hyperlipidemia. The study is randomized, double-blind, and placebo-controlled, enrolling approximately 36 subjects. Interim biomarker data is expected in July 2025, with topline results anticipated in Q3 2025. Current IPF treatments are limited and come with significant side effects, highlighting the unmet need for safer alternatives. Positive safety results and ongoing study progression could significantly enhance GRI Bio's market position and investor sentiment.

GRI Bio, Inc. presented positive preclinical data at the 2025 ATS International Conference, demonstrating that GRI-0621 has anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis. The data, shared by CEO Marc Hertz, supports ongoing Phase 2a clinical trials for GRI-0621 in treating Idiopathic Pulmonary Fibrosis (IPF). Interim results from the Phase 2a study indicate GRI-0621 is safe and well-tolerated, with no significant adverse effects observed. The company anticipates further results from the study in Q3 2025, highlighting the potential of GRI-0621 as a treatment option for IPF, a condition with significant unmet medical needs. Positive preclinical and interim clinical results suggest significant potential for GRI-0621 to impact treatment options for IPF, a serious condition.

GRI Bio, Inc. (NASDAQ: GRI) will participate in the Virtual Investor Closing Bell Series on May 28, 2025, at 4:00 PM ET, where CEO Marc Hertz will present a corporate overview and business outlook. Investors can submit questions during the event, which will be available via live webcast on the company's website, with a replay accessible for 90 days. GRI Bio focuses on developing NKT cell modulators for treating inflammatory, fibrotic, and autoimmune diseases, with its lead program, GRI-0621, targeting idiopathic pulmonary fibrosis. Participation in the investor event may enhance visibility and investor engagement, potentially influencing market sentiment.

GRI Bio, Inc. (NASDAQ: GRI) announced that CEO Marc Hertz, PhD, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025, at 2:40 PM ET. The event will be held virtually, and a live webcast will be available on the company's website. GRI Bio focuses on developing Natural Killer T cell modulators for treating inflammatory, fibrotic, and autoimmune diseases, with its lead program, GRI-0621, targeting idiopathic pulmonary fibrosis. Participation in a significant healthcare showcase may enhance visibility and investor interest in GRI Bio's innovative therapies.

GRI Bio, Inc. reported its financial results for the first quarter of 2025, confirming that the Phase 2a trial of GRI-0621 for idiopathic pulmonary fibrosis (IPF) is on schedule. The company anticipates releasing 6-week interim data in Q2 2025 and topline data in Q3 2025. The upcoming interim and topline data releases for GRI-0621 could significantly influence investor sentiment and the company's future trajectory.